Evidence map›Paper›PMID 26238952›Full record

ArticleInternational journal of radiation oncology, biology, physics2015

Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.

Daniel L J Thorek, Robin M Kramer, Qing Chen, Jeho Jeong, Mihaela E Lupu, Alycia M Lee, Mary E Moynahan, Maeve Lowery, David Ulmert, Pat Zanzonico and 3 more

Abstract readEvaluation StudyValidation Study
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Daniel L J ThorekDivision of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins School of Medicine, Baltimore, MD. Electronic address: dthorek1@jhmi.edu.
Robin M KramerTri-Institutional Training Program in Laboratory Animal Medicine and Science, Memorial Sloan-Kettering Cancer Center (MSKCC), Weill Cornell Medical College, The Rockefeller University, New York, NY.
Qing ChenDepartment of Medical Physics, MSKCC, New York, NY.
Jeho JeongDepartment of Medical Physics, MSKCC, New York, NY.
Mihaela E LupuDepartment of Medical Physics, MSKCC, New York, NY.
Alycia M LeeDepartment of Medicine, MSKCC, New York, NY.
Mary E MoynahanDepartment of Medicine, MSKCC, New York, NY.
Maeve LoweryDepartment of Medicine, MSKCC, New York, NY.
David UlmertMolecular Pharmacology and Chemistry Program, MSKCC, New York, NY; Department of Surgery (Urology), Skåne University Hospital, Malmö, Sweden.
Pat ZanzonicoDepartment of Medical Physics, MSKCC, New York, NY.
Joseph O DeasyDepartment of Medical Physics, MSKCC, New York, NY.
John L HummDepartment of Medical Physics, MSKCC, New York, NY.
James RussellDepartment of Medical Physics, MSKCC, New York, NY. Electronic address: russellj@mskcc.org.
Jamestown Community College · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USSkåne University Hospital · SE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Molecular Imaging: Training for OncologyR25CA096945 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HRICAK, HEDVIG · 2002 to 2013
$5.2M
The Inveon PET/CT for Pre-Clinical Oncology ResearchS10OD012307 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2012 to 2012
$1.0M
NanoSPECT/CT for Oncology ResearchS10RR028889 · NCRR · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2011 to 2011
$907k
SHARED INSTRUMENT: FOCUS MICROPET: CANCERS10RR020892 · NCRR · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2005 to 2005
$499k
Tri-Institutional Training Program in Laboratory Animal Medicine and ScienceR25OD010447 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LIPMAN, NEIL SCOTT · 2012 to 2015
$474k
NCI NIH HHS 5R25CA096945-07NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA008748-48NCI NIH HHS R25 CA096945NCRR NIH HHS S10 RR020892NCRR NIH HHS S10 RR020892-01NCRR NIH HHS S10 RR028889NCRR NIH HHS S10 RR028889-01NIH HHS R25 OD010447NIH HHS R25-OD010447-02NIH HHS S10 OD012307
6 · The paper itself

Abstract

purposeTo evaluate the feasibility of delivering experimental radiation therapy to tumors in the mouse pancreas. Imaging and treatment were performed using combined CT (computed tomography)/orthovoltage treatment with a rotating gantry. METHODS AND MATERIALS: After intraperitoneal administration of radiopaque iodinated contrast, abdominal organ delineation was performed by x-ray CT. With this technique we delineated the pancreas and both orthotopic xenografts and genetically engineered disease. Computed tomographic imaging was validated by comparison with magnetic resonance imaging. Therapeutic radiation was delivered via a 1-cm diameter field. Selective x-ray radiation therapy of the noninvasively defined orthotopic mass was confirmed using γH2AX staining. Mice could tolerate a dose of 15 Gy when the field was centered on the pancreas tail, and treatment was delivered as a continuous 360° arc. This strategy was then used for radiation therapy planning for selective delivery of therapeutic x-ray radiation therapy to orthotopic tumors.

resultsTumor growth delay after 15 Gy was monitored, using CT and ultrasound to determine the tumor volume at various times after treatment. Our strategy enables the use of clinical radiation oncology approaches to treat experimental tumors in the pancreas of small animals for the first time. We demonstrate that delivery of 15 Gy from a rotating gantry minimizes background healthy tissue damage and significantly retards tumor growth.

conclusionsThis advance permits evaluation of radiation planning and dosing parameters. Accurate noninvasive longitudinal imaging and monitoring of tumor progression and therapeutic response in preclinical models is now possible and can be expected to more effectively evaluate pancreatic cancer disease and therapeutic response.

Indexed as

Contrast MediaAnimalsDisease Models, AnimalFeasibility StudiesFemaleHeterograftsHistonesInjections, IntraperitonealMagnetic Resonance ImagingMedical IllustrationMiceMice, Inbred BALB CMice, NudePancreatic NeoplasmsRadiotherapy DosageRadiotherapy, Image-GuidedContrast Mediagamma-H2AX protein, mouseHistones

Identifiers

PMID26238952
PMCPMC4575601
OpenAlexW2108475931

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.